The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues

References

• Tracy JI, Josiassen RC, Bellack A. Neuropsychology of dual diagnosis: understanding the combined effects of schizophrenia and substance use disorders. Clin Psychol Rev 1995; 15: 67–97
   Web of Science ®Google Scholar
• Barnes M, Lawford BR, Burton SC, et al. Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use?. Aust N Z J Psychiatry 2006; 40: 575–580
   PubMed Web of Science ®Google Scholar
• Dolan SL, Sacco KA, Termine A, et al. Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia. Schizophr Res 2004; 70: 263–275
   PubMed Web of Science ®Google Scholar
• Evins AE, Deckersbach T, Cather C, et al. Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. J Clin Psychiatry 2005; 66: 1184–1190
   PubMed Web of Science ®Google Scholar
• Faucher AL. Antisaccades, smoking and schizophrenia: evidence for a cognitive benefit of nicotine. Dissertation Abstr Int B Sci Eng 2001; 62: 1B
   Google Scholar
• George TP, Vessicchio JC, Termine A, et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 2002; 26: 75–85
   PubMed Web of Science ®Google Scholar
• Harris JG, Kongs S, Allensworth D, et al. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology 2004; 29: 1378–1385
   PubMed Web of Science ®Google Scholar
• Jacobsen LK, D'Souza DC, Mencl WE, Pugh KR, Skudlarski P, Krystal JH. Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry 2004; 55: 850–858
   PubMed Web of Science ®Google Scholar
• Klein C, Andresen B. On the influence of smoking upon smooth pursuit eye movements of schizophrenics and normal controls. J Psychophysiol 1991; 5: 361–369
   Google Scholar
• Larrison–Faucher AL, Matorin AA, Sereno AB. Nicotine reduces antisaccades errors in task impaired schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 505–516
   PubMed Web of Science ®Google Scholar
• Levin ED, Wilson W, Rose JE, McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996; 15: 429–436
   PubMed Web of Science ®Google Scholar
• Mosnik DM. Effects of cigarette smoking and withdrawal on cognitive performance and psychopathology in patients with schizophrenia compared to normal controls. Dissertation Abstr Int B Sci Eng 2001; 61: 9B
   Google Scholar
• Muggli L. Understanding the relationship between smoking and cognitive functioning in schizophrenia. Dissertation Abstr Int B Sci Eng 2005; 66: 4B
   Google Scholar
• Myers CS, Robles O, Kakoyannis AN, et al. Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology 2004; 174: 334–340
   PubMed Web of Science ®Google Scholar
• Riala K, Hakko H, Isohanni M, Jokelainen J, Weiser M, Rasanen P. Poor premorbid school performance is associated with later cigarette smoking among schizophrenia patients. Psychiatry Res 2005; 137: 137–141
   PubMed Web of Science ®Google Scholar
• Sacco KA, Termine A, Seyal A, et al. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 2005; 62: 649–659
   PubMed Web of Science ®Google Scholar
• Sacco KA, Termine A, Dudas MM, et al. Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist. Schizophr Res 2006; 85: 213–221
   PubMed Web of Science ®Google Scholar
• Sandyk R. Cigarette smoking: effects on cognitive functions and drug-induced parkinsonism in chronic schizophrenia. Int J Neurosci 1993; 70: 193–197
   PubMed Web of Science ®Google Scholar
• Smith RC, Singh A, Infante M, Khandat A, Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 2002; 27: 479–497
   PubMed Web of Science ®Google Scholar
• Taiminen TJ, Salokangas RKR, Saarijarvi S, et al. Smoking and cognitive deficits in schizophrenia: a pilot study. Addict Behav 1998; 23: 263–266
   PubMed Web of Science ®Google Scholar
• Tracy JI, Monaco C, Giovannetti T, Abraham G, Josiassen R. The effects of ‘acute’ cigarette smoking on cognitive functioning in chronic schizophrenia. Cognit Neuropsychiatry 2000; 5: 193–217
   Google Scholar
• Allen DN, Goldstein G, Aldarondo F. Neurocognitive dysfunction in patients diagnosed with schizophrenia and alcoholism. Neuropsychology 1999; 13: 62–68
   PubMed Web of Science ®Google Scholar
• Bowie CR. Neurocognition, symptomatology, and social-adaptive functioning in alcohol-abusing schizophrenia patients. Dissertation Abstr Int B Sci Eng 2003; 63: 11B
   Google Scholar
• Bowie CR, Serper MR, Riggio S, Harvey PD. Neurocognition, symptomatology, and functional skills in older alcohol-abusing schizophrenia patients. Schizophr Bull 2005; 31: 175–182
   PubMed Web of Science ®Google Scholar
• Goldstein G, Allen DN, Sanders RD. Sensory-perceptual dysfunction in patients with schizophrenia and comorbid alcoholism. J Clin Exp Neuropsychol 2002; 24: 1010–1016
   PubMed Web of Science ®Google Scholar
• Liraud F, Verdoux H. Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders. Encephale 2002; 28:160–168 (in French).
   PubMed Web of Science ®Google Scholar
• Manning V, Wanigaratne S, Best D, Strathdee G, Schrover I, Gossop M. Screening for cognitive functioning in psychiatric outpatients with schizophrenia, alcohol dependence, and dual diagnosis. Schizophr Res 2007; 91: 151–158
   PubMed Web of Science ®Google Scholar
• Meydan J, Liu X, Hasin D. Alcohol and drug use in schizophrenia as predictors of functional impairment. Schizophr Res 2005; 77: 105–106
   PubMed Web of Science ®Google Scholar
• Mohamed S, Bondi M, Kasckow JW, Golshan S, Jeste DV. Neurocognitive functioning in dually diagnosed middle aged and elderly patients with alcoholism and schizophrenia. Int J Geriatr Psychiatry 2006; 21: 711–718
   PubMed Web of Science ®Google Scholar
• Nazzaro DM. Neuropsychological differences between patients diagnosed with schizophrenia and comorbid schizophrenia and alcohol dependence. Dissertation Abstr Int B Sci Eng 2002; 63: 5B
   Google Scholar
• Nixon SJ, Hallford HG, Tivis RD. Neurocognitive function in alcoholic, schizophrenic, and dually diagnosed patients. Psychiatry Res 1996; 64: 35–45
   PubMed Web of Science ®Google Scholar
• Pencer A, Addington J. Substance use and cognition in early psychosis. J Psychiatry Neurosci 2003; 28: 48–54
   PubMed Web of Science ®Google Scholar
• Reardon ML. Prediction of comorbid alcohol use disorders using factors derived from the Positive and Negative Syndrome Scale in an inpatient psychiatric hospital. Dissertation Abstr Int B Sci Eng 2005; 65: 12B
   Google Scholar
• Remy CJ. The relationship between performance on memory tests and treatment efficacy for patients with comorbid schizophrenia and substance use disorders. Dissertation Abstr Int B Sci Eng 1999; 60: 4B
   Google Scholar
• Snyder AG. The neurocognitive functioning of dually diagnosed patients with schizophrenia and a substance abuse disorder. Dissertation Abstr Int B Sci Eng 1998; 59: 6-B
   Google Scholar
• Thoma RJ, Hanlon FM, Miller GA, et al. Neuropsychological and sensory gating deficits related to remote alcohol abuse history in schizophrenia. J Int Neuropsychol Soc 2006; 12: 34–44
   PubMed Web of Science ®Google Scholar
• Cooper L. The relationship between neuropsychological functioning and length of abstinence in schizophrenic cocaine users. Dissertation Abstr Int B Sci Eng 1996; 57: 6B
   Google Scholar
• Cooper L, Liberman D, Tucker D, Neuchterlein KH, Tsuang J, Barnett HL. Neurocognitive deficits in the dually diagnosed with schizophrenia and cocaine abuse. Psychiatr Rehabil Skills 1999; 3: 231–245
   Google Scholar
• Copersino ML, Serper MR, Vadhan N, et al. Cocaine craving and attentional bias in cocaine-dependent schizophrenic patients. Psychiatry Res 2004; 128: 209–218
   PubMed Web of Science ®Google Scholar
• Serper MR, Bergman A, Copersino ML, Chou JCY, Richarme D, Cancro R. Learning and memory impairment in cocaine-dependent and comorbid schizophrenic patients. Psychiatry Res 2000; 93: 21–32
   PubMed Web of Science ®Google Scholar
• Serper MR, Copersino ML, Richarme D, Vadhan N, Cancro R. Neurocognitive functioning in recently abstinent, cocaine-abusing schizophrenic patients. J Subst Abuse 2000; 11: 205–213
   PubMedGoogle Scholar
• Sevy S, Kay SR, Opler L, van Praag HM. Significance of cocaine history in schizophrenia. J Nerv Ment Dis 1990; 178: 642–648
   PubMed Web of Science ®Google Scholar
• Smelson D, Davis CW, Di Pano R, Johnson V, Losonczy MF, Ziedonis D. Executive and motor skill functioning among cocaine-dependent schizophrenics and non-drug abusing schizophrenics. J Nerv Ment Dis 2002; 190: 200–202
   PubMed Web of Science ®Google Scholar
• Smelson DA, Davis CW, Eisenstein N, et al. Cognitive disparity in schizophrenics with and without cocaine dependency. J Subst Abuse Treat 2003; 24: 75–79
   PubMed Web of Science ®Google Scholar
• Barch DM, Carter CS. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res 2005; 77: 43–58
   PubMed Web of Science ®Google Scholar
• Goldberg TE, Bigelow LB, Weinberger DR, Daniel DG, Kleinman JE. Cognitive and behavioural effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry 1991; 148: 78–84
   PubMed Web of Science ®Google Scholar
• Murakami T, Nakagome K, Kamio S, et al. The effects of benzodiazepines on event-related potential indices of automatic and controlled processing in schizophrenia: a preliminary report. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 651–661
   PubMed Web of Science ®Google Scholar
• Addington J, Addington D. Substance abuse and cognitive functioning in schizophrenia. J Psychiatry Neurosci 1997; 22: 99–104
   PubMed Web of Science ®Google Scholar
• Carey KB, Carey MP, Simons JS. Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status. J Nerv Ment Dis 2003; 191: 300–308
   PubMed Web of Science ®Google Scholar
• Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown GM, Franco S. Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function. J Clin Psychiatry 1991; 52: 26–30
   PubMed Web of Science ®Google Scholar
• Herman M. Neurocognitive functioning and quality of life among dually diagnosed and non-substance abusing schizophrenia inpatients. Int J Ment Health Nurs 2004; 13: 282–291
   PubMed Web of Science ®Google Scholar
• Joyal CC, Hallé P, Lapierre D, Hodgins S. Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophr Res 2003; 63: 297–299
   PubMed Web of Science ®Google Scholar
• McCleery A, Addington J, Addington D. Substance misuse and cognitive functioning in early psychosis: a 2 year follow-up. Schizophr Res 2006; 88: 187–191
   PubMed Web of Science ®Google Scholar
• Potvin S, Briand C, Prouteau A, et al. CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain Cogn 2005; 59: 38–42
   PubMed Web of Science ®Google Scholar
• Sevy S, Robinson DG, Solloway S, et al. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 2001; 104: 367–374
   PubMed Web of Science ®Google Scholar
• Thoma P, Wiebel B, Daum I. Response inhibition and cognitive flexibility in schizophrenia with and without comorbid substance use disorder. Schizophr Res 2007; 92: 168–180
   PubMed Web of Science ®Google Scholar
• D'Souza DC, Perry E, MacDougall L, et al. The psychotomimetic effects of delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29: 1558–1572
   PubMed Web of Science ®Google Scholar
• D'Souza DC, Abi-Saab WM, Madonick S, et al. Δ9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57: 594–608
   PubMed Web of Science ®Google Scholar
• Kumra S, Thaden E, DeThomas C, Kranzler H. Correlates of substance abuse in adolescents with treatment-refractory schizophrenia and schizoaffective disorder. Schizophr Res 2005; 73: 369–371
   PubMed Web of Science ®Google Scholar
• Stirling J, White C, Lewis S, et al. Neurocognitive function and outcome in first-episode schizophrenia: A 10-year follow-up of an epidemiological cohort. Schizophr Res 2003; 65: 75–86
   PubMed Web of Science ®Google Scholar
• Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr Res 2005; 75: 135–137
   PubMed Web of Science ®Google Scholar
• Jockers-Scherübl MC, Wolf T, Radzei N, et al. Cannabis induces different cognitive changes in schizophrenic patients and healthy controls. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1054–1063
   PubMed Web of Science ®Google Scholar
• Sevy S, Burdick KE, Visweswaraiah H, et al. Iowa Gambling Task in schizophrenia: a review and new data in patients with schizophrenia and co-occurring cannabis use disorders. Schizophr Res 2007; 92: 74–84
   PubMed Web of Science ®Google Scholar
• Duke P, Pantelis C, McPhillips MA, Barnes TRE. Comorbid non-alcohol substance misuse among people with schizophrenia: epidemiological study in ventral London. Br J Psychiatry 2001; 179: 509–513
   PubMed Web of Science ®Google Scholar
• Kavanagh DJ, Waghorn G, Jenner L, et al. Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophr Res 2004; 66: 115–124
   PubMed Web of Science ®Google Scholar
• Mueser KT, Yarnold PR, Rosenberg SD, Swett C, Miles KM, Hill D. Substance use disorder in hospitalised severely mentally ill psychiatric patients: prevalence, correlates, and subgroups. Schizophr Bull 2000; 26: 179–192
   PubMed Web of Science ®Google Scholar
• Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination and evidence. Br J Psychiatry 2004; 184: 110–117
   PubMed Web of Science ®Google Scholar
• Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001; 50: 71–83
   PubMed Web of Science ®Google Scholar
• Negrete JC, Gill K. Cannabis and schizophrenia: an overview of the evidence to date. Marijuana and Medicine, GG Nahas, KM Sutin, D Harvey, S Agurrel. Humana Press, New Jersey 1999; 671–681
   Google Scholar
• van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002; 156: 319–327
   PubMed Web of Science ®Google Scholar
• Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002; 325: 1212–1213
   PubMed Web of Science ®Google Scholar
• Smit F, Bolier L, Cuijpers P. Cannabis use and the risk of later schizophrenia: a review. Addiction 2004; 99: 425–430
   PubMed Web of Science ®Google Scholar
• Pantelis C, Maruff P. The cognitive neuropsychiatric approach to investigating the neurobiology of schizophrenia and other disorders. J Psychosom Res 2002; 53: 655–664
   PubMed Web of Science ®Google Scholar
• Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001; 178: 101–106
   PubMed Web of Science ®Google Scholar
• Solowij N. Cannabis and cognitive functioning. Cambridge University Press, CambridgeUK 1998
   Google Scholar
• Goodarzi MA, Wykes T, Hemsley DR. Cerebral lateralization of global-local processing in people with schizotypy. Schizophr Res 2000; 45: 115–121
   PubMed Web of Science ®Google Scholar
• John CH, Hemsley DR. Gestalt perception in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1992; 241: 215–221
   PubMed Web of Science ®Google Scholar
• Peters ER, Pickering AD, Kent A, et al. Perceptual organization deficits in psychotic patients. Psychiatry Res 2000; 110: 125–135
   Web of Science ®Google Scholar
• Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 1997; 66: 803–807
   Web of Science ®Google Scholar
• Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM. Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav 2000; 66: 175–181
   PubMed Web of Science ®Google Scholar
• Schneider U, Leweke FM, Mueller-Vahl KR, Emrich HM. Cannabinoid/anandamide system and schizophrenia: is there evidence for association?. Pharmacopsychiatry 1998; 31(Suppl)110–113
   Google Scholar
• Antonova E, Sharma T, Morris R, Kumari V. The relationship between brain structure and neurocognition in schizophrenia: a selective review. Schizophr Res 2004; 70: 117–145
   PubMed Web of Science ®Google Scholar
• Goldstein JM, Seidman LJ, Santangelo S, Knapp PH, Tsuang MT. Are schizophrenic men at higher risk for developmental deficits than schizophrenic women? Implications for adult neuropsychological functions. J Psychiatr Res 1994; 28: 483–498
   PubMed Web of Science ®Google Scholar
• Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42: 327–360
   PubMed Web of Science ®Google Scholar
• O'Leary DS, Block RI, Koeppel JA, et al. Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 2002; 26: 802–816
   PubMed Web of Science ®Google Scholar
• Vik PW, Cellucci T, Jarchow A, Hedt J. Cognitive impairment in substance abuse. Psychiatr Clin North Am 2004; 27: 97–109
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental Disorders, 4th edn. Washington, DC: American Psychiatric Press, 1994.
   Google Scholar
• Pope HG, Gruber AJ, Hudson JI, Huestis M, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58: 909–915
   PubMed Web of Science ®Google Scholar
• Richtand NM, Woods SC, Berger SP, Strakowski SM. D3 dopamine receptor, behavioural sensitisation, and psychosis. Neurosci Biobehav Rev 2001; 25: 427–443
   PubMed Web of Science ®Google Scholar
• Brown J, Kranzler HR, Del Boca F. Self-reports by alcohol and drug abuse inpatients: factors affecting reliability and validity. Br J Addict 1992; 87: 1013–1024
   PubMedGoogle Scholar
• Leduc PA, Mittleman G. Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. Psychopharmacology 1995; 121: 407–427
   PubMed Web of Science ®Google Scholar
• Wilkins JN, Shaner AL, Patterson CM, Setoda D, Gorelick D. Discrepancies between patient report, clinical assessment, and urine analysis in psychiatric patients during inpatient admission. Psychopharmacol Bull 1991; 27: 149–154
   PubMedGoogle Scholar
• Potkin SG, Fleming K, Jin Y, Gulasekaram B. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J Clin Psychopharmacol 2001; 21: 479–483
   PubMed Web of Science ®Google Scholar
• Potvin S, Stip E, Roy J-Y. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. Int Clin Psychopharmacol 2003; 18: 121–132
   PubMed Web of Science ®Google Scholar
• Velligan DI, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol?. Schizophr Res 2002; 53: 239–248
   PubMed Web of Science ®Google Scholar
• Paleacu D, Shutzman A, Giladi N, Herman T, Simon ES, Hausdorff JM. Effects of pharmacological therapy on gait and cognitive function in depressed patients. Clin Neuropharmacol 2007; 30: 63–71
   PubMed Web of Science ®Google Scholar
• Hessen E, Lossius MI, Reinvang I, Gjerstad L. Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy. Epilepsia 2006; 47: 2038–2045
   PubMed Web of Science ®Google Scholar
• Barker MJ, Greenwood KM, Jackson M, Crowe SF. An evaluation of persisting cognitive effects after withdrawal from long-term benzodiazepine use. J Int Neuropsychol Soc 2005; 11: 281–289
   PubMed Web of Science ®Google Scholar
• Bottiggi KA, Salazar JC, Yu L, et al. Long-term cognitive impact of anticholinergic medications in older adults. Am J Geriatr Psychiatry 2006; 14: 980–984
   PubMed Web of Science ®Google Scholar
• Basso MR, Nasrallah HA, Olson SC, Bornstein RA. Neuropsychological correlates of negative, disorganised and psychotic symptoms in schizophrenia. Schizophr Res 1998; 31: 99–111
   PubMed Web of Science ®Google Scholar
• Zakzanis K. Neuropsychological correlates of positive vs negative schizophrenic symptomatology. Schizophr Res 1998; 29: 227–233
   PubMed Web of Science ®Google Scholar
• Dolan RJ, Bench CJ, Brown RG, Scott LC, Frackowiak RS. Neuropsychological dysfunction in depression: the relationship to regional cerebral blood flow. Psychol Med 1994; 24: 849–857
   PubMed Web of Science ®Google Scholar
• Klasik A, Janas-Kozik M, Krupka-Matuszczyk I. Influence of anxiety on cognitive functions’ disturbances in adolescents and young adults diagnosed with paranoid schizophrenia. Przeglad Lekarski 2006; 63 (Suppl 1):35–43 (in Polish).
   PubMedGoogle Scholar
• Bellino S, Rocca P, Patria L, et al. Relationship of age at onset with clinical features and cognitive functions in a sample of schizophrenia patients. J Clin Psychiatry 2004; 65: 908–914
   PubMed Web of Science ®Google Scholar
• Russell AJ, Munro JC, Jones PB, Hemsley DR, Murray RM. Schizophrenia and the myth of intellectual decline. Am J Psychiatry 1997; 154: 635–639
   PubMed Web of Science ®Google Scholar
• Lidow MS, Elsworth JD, Goldman-Rakic PS. Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J Pharmacol Exp Ther 1997; 281: 597–603
   PubMed Web of Science ®Google Scholar
• Schmitt A, Zink M, Petroianu G, May B, Braus DF, Henn FA. Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain. Neurosci Lett 2003; 347: 81–84
   PubMed Web of Science ®Google Scholar
• Gray JA, Roth BL. Paradoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists. Brain Res Bull 2001; 56: 441–451
   PubMed Web of Science ®Google Scholar
• Hietala J, Kuoppamäki M, Majasuo H, Pälvimäki E-P, Laakso A, Syvälahti E. Sertindole is a serotonin 5-HT2C inverse agonist and decreases agonist but not antagonist binding to 5-HT2C receptors after chronic treatment. Psychopharmacology 2001; 157: 180–187
   PubMed Web of Science ®Google Scholar
• Richtand NM, Welge JA, Levant B, et al. Altered behavioural response to dopamine D3 receptor agonists 7-OH-DPAT and PD 128907 following repetitive amphetamine administration. Neuropsychopharmacology 2003; 28: 1422–1432
   PubMed Web of Science ®Google Scholar
• Pope HG, Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association?. Drug Alcohol Depend 2003; 69: 303–310
   PubMed Web of Science ®Google Scholar
• de Leon J, Diaz FJ, Rogers T, Browne D, Dinsmore L. Initiation of daily smoking and nicotine dependence in schizophrenia and mood disorders. Schizophr Res 2002; 56: 47–54
   PubMed Web of Science ®Google Scholar
• Leonard S, Adler LE, Benhammou K, et al. Smoking and mental illness. Pharmacol Biochem Behav 2001; 70: 561–570
   PubMed Web of Science ®Google Scholar
• Lyon ER. A review of the effects of nicotine on schizophrenia and antipsychotic medications. Psychiatr Serv 1999; 50: 1346–1350
   PubMed Web of Science ®Google Scholar
• Smith RC, Infante M, Ali A, Nigam S, Kotsaftis A. Effects of cigarette smoking on psychopathology scores in patients with schizophrenia: an experimental study. Subst Abus 2001; 22: 175–186
   PubMedGoogle Scholar
• Breese CR, Lee MJ, Adams CE, et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 2000; 23: 351–364
   PubMed Web of Science ®Google Scholar
• Dalack G, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 1998; 155: 1490–1501
   PubMed Web of Science ®Google Scholar
• Griffith JM, O'Neill JE, Petty F, Garver D, Young D, Freedman R. Nicotinic receptor desensitisation and sensory gating deficits in schizophrenia. Biol Psychiatry 1998; 44: 98–106
   PubMed Web of Science ®Google Scholar
• George TP, Verrico CD, Picciotto MR, Roth RH. Nicotinic modulation of mesoprefrontal dopamine neurons: pharmacologic and neuroanatomic characterization. J Pharmacol Exp Ther 2000; 295: 58–66
   PubMed Web of Science ®Google Scholar
• Paton C, Beer D. Caffeine: the forgotten variable. Int J Psychiatry Clin Pract 2001; 5: 231–236
   PubMed Web of Science ®Google Scholar
• Kruger A. Chronic psychiatric patients’ use of caffeine: pharmacological effects and mechanisms. Psychol Rep 1996; 78: 915–923
   PubMed Web of Science ®Google Scholar
• Simmons DH. Caffeine and its effect on persons with mental disorders. Arch Psychiatr Nurs 1996; 10: 116–122
   PubMed Web of Science ®Google Scholar
• Schapkin SA. Influence of caffeine on physiological and cognitive functions of humans. Hum Physiol 2002; 28: 144–150
   Google Scholar
• Hughes JR, McHugh P, Holtzman S. Caffeine and schizophrenia. Psychiatr Serv 1998; 49: 1415–1417
   PubMed Web of Science ®Google Scholar
• Rihs M, Müller C, Baumann P. Caffeine consumption in hospitalised psychiatric patients. Eur Arch Psychiatry Clin Neurosci 1996; 246: 83–92
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Kanazawa I. Acute effects of cigarettes in non-deprived smokers on memory, calculation and executive functions. Hum Psychopharmacol Clin Exp 2002; 17: 369–373
   PubMed Web of Science ®Google Scholar
• Corcoran C, Malaspina D. Traumatic brain injury and risk for schizophrenia. Int J Ment Health 2001; 30: 17–32
   Google Scholar
• Freudenreich O, Weiner RD, McEvoy JP. Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. Biol Psychiatry 1997; 42: 132–137
   PubMed Web of Science ®Google Scholar
• Hyde TM, Weinberger DR. Seizures and schizophrenia. Schizophr Bull 1997; 23: 611–622
   PubMed Web of Science ®Google Scholar
• Malaspina D, Goetz RR, Friedman JH, et al. Traumatic brain injury and schizophrenia in members of schizophrenia and bipolar disorder pedigrees. Am J Psychiatry 2001; 158: 440–446
   PubMed Web of Science ®Google Scholar
• Malik PA, Husted J, Chow EWC, Bassett AS. Childhood head injury and expression of schizophrenia in multiply affected families. Arch Gen Psychiatry 2003; 60: 231–236
   PubMed Web of Science ®Google Scholar
• Keshavan MS, Sujata M, Mehra A, Montrose DM, Sweeney JA. Psychosis proneness and ADHD in young relatives of schizophrenia patients. Schizophr Res 2002; 59: 85–92
   Web of Science ®Google Scholar
• Tzelepis A, Schubiner H, Warbasse L. Differential diagnosis and psychiatric comorbidity patterns in adult attention deficit disorder. A comprehensive guide to attention deficit disorder in adults: research, diagnosis, and treatment, KG Nadeau. Brunner/Mazel, PhiladelphiaUS 1995; 35–37
   Google Scholar
• Richardson AJ. Dyslexia and schizotypy. Schizotypy: implications for illness and health, G Claridge. Oxford University Press, London 1997; 171–201
   Google Scholar
• Verbaten M, van Engeland H. (Neuro)physiologic similarities between childhood developmental disorders and schizophrenia. Advances in the neurobiology of schizophrenia. Wiley series on clinical and neurobiological advances in psychiatry, JA Den Boer, HGM Westenberg, HM van Praag. John Wiley & Sons, Oxford 1995; 1: 369–400
   Google Scholar
• Virtue C, Iqbal N, Masur D, Schwartz B. Developmental disorder or schizophrenia?. Am J Psychiatry 1993; 150: 521
   PubMed Web of Science ®Google Scholar
• Hemsley DR. Attention and information processing in schizophrenia. Br J Soc Clin Psychol 1976; 15: 199–209
   PubMed Web of Science ®Google Scholar
• Hemsley DR. Perception and cognition in schizophrenia. Schizophrenia: origins, processes, treatment, and outcome, RL Cromwell, CR Snyder. Oxford University Press, London 1993; 135–150
   Google Scholar
• Hemsley DR. A simple (or simplistic?) cognitive model for schizophrenia. Behav Res Ther 1993; 31: 633–645
   PubMed Web of Science ®Google Scholar
• Mueser KT, McGurk SR. Schizophrenia. Lancet 2004; 363: 2063–2072
   PubMed Web of Science ®Google Scholar
• Peters ER, Nunn JA, Pickering AD, Hemsley DR. Perceptual organization deficits in psychotic patients. Psychiatry Res 2002; 110: 125–135
   PubMed Web of Science ®Google Scholar
• Seaton BE, Goldstein G, Allen DN. Sources of heterogeneity in schizophrenia: the role of neuropsychological functioning. Neuropsychol Rev 2001; 11: 45–66
   PubMed Web of Science ®Google Scholar
• Semple DM, Ramsden F, McIntosh AM. Reduced binocular depth inversion in regular cannabis users. Pharmacol Biochem Behav 2003; 75: 789–793
   PubMed Web of Science ®Google Scholar
• Solowij N, Stephens RS, Roffman RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287: 1123–1131
   PubMed Web of Science ®Google Scholar
• Ruff RM, Allen CC. Ruff 2 and 7 Selective Attention Test: professional manual. Psychological Assessment Resources, San Francisco 1996
   Google Scholar
• Spreen O, Strauss E. A compendium of neuropsychological tests: administration, norms, and commentary2nd edn. Oxford University Press, Oxford 1998
   Google Scholar
• Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006; 19: 233–238
   PubMed Web of Science ®Google Scholar
• Kouri EM, Pope HG. Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol 2000; 8: 483–492
   PubMed Web of Science ®Google Scholar
• Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and significance of cannabis withdrawal. J Abnorm Psychol 2003; 112: 393–402
   PubMed Web of Science ®Google Scholar
• Grant I, Gonzalez R, Carey CL, Natarajan L, Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc 2003; 9: 679–689
   PubMed Web of Science ®Google Scholar
• Kathmann M, Bauer U, Schlicker E, Göthert M. Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainite-stimulated noradrenaline and dopamine release in the brain. Naunyn Schmiedebergs Arch Pharmacol 1999; 359: 466–470
   PubMed Web of Science ®Google Scholar
• Pistis M, Ferraro L, Pira L, et al. Δ9-Tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 2002; 948: 155–158
   PubMed Web of Science ®Google Scholar
• Loeber RT, Yurgelun-Todd DA. Human neuroimaging of acute and chronic marijuana use: implications for frontocerebellar dysfunction. Hum Psychopharmacol Clin Exp 1999; 14: 291–304
   Web of Science ®Google Scholar
• Diana M, Melis M, Gessa GL. Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur J Neurosci 1998; 10: 2825–2830
   PubMed Web of Science ®Google Scholar
• Jentsch JD, Andrusiak E, Tran A, Bowers MB, Roth RH. Δ9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. Neuropsychopharmacology 1996; 16: 426–432
   Web of Science ®Google Scholar
• Acquas E, Pisanu A, Marrocu P, Goldberg SR, Di Chiara G. Δ9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study. Eur J Pharmacol 2001; 419: 155–161
   PubMed Web of Science ®Google Scholar
• Verrico CD, Jentsch JD, Dazzi L, Roth RH. Systemic, but not local, administration of cannabinoid CB1 receptor agonists modulate prefrontal cortical acetylcholine efflux in the rat. Synapse 2003; 48: 178–183
   PubMed Web of Science ®Google Scholar
• Ferraro L, Tomasini MC, Gessa GL, Bebe BW, Tanganelli S, Antonelli T. The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study. Cereb Cortex 2001; 11: 728–733
   PubMed Web of Science ®Google Scholar
• Kim JJ, Mohamed S, Andreasen NC, et al. Regional neural dysfunctions in chronic schizophrenia studied with positron emission tomography. Am J Psychiatry 2000; 157: 542–548
   PubMed Web of Science ®Google Scholar
• Potkin SG, Alva G, Fleming K, et al. A PET study of the pathophysiology of negative symptoms in schizophrenia. Am J Psychiatry 2002; 159: 227–237
   PubMed Web of Science ®Google Scholar
• Vance ALA, Velakoulis D, Maruff P, Wood PD, Pantelis C. Magnetic resonance spectroscopy and schizophrenia: what have we learnt?. Aust N Z J Psychiatry 2000; 34: 14–25
   PubMed Web of Science ®Google Scholar
• Velakoulis D, Pantelis C. What have we learned from functional imaging studies in schizophrenia? The role of frontal, striatal and temporal areas. Aust N Z J Psychiatry 1996; 30: 195–209
   PubMed Web of Science ®Google Scholar
• Wood SJ, Berger G, Velakoulis D, et al. Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophr Bull 2003; 29: 831–843
   PubMed Web of Science ®Google Scholar
• Breivogel CS, Childers SR. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis 1998; 5: 417–431
   PubMed Web of Science ®Google Scholar
• Gifford AN, Makriyannis A, Volkow ND, Gatley J. In vivo imaging of the brain cannabinoid receptor. Chem Phys Lipids 2002; 121: 65–72
   PubMed Web of Science ®Google Scholar
• Ilan AB, Smith ME, Gevins A. Effects of marijuana on neurophysiological signals of working and episodic memory. Psychopharmacology 2004; 176: 214–222
   PubMed Web of Science ®Google Scholar
• Shah YB, Prior MJW, Dixon AL, Morris PG, Marsden CA. Detections of cannabinoid agonist evoked increase in BOLD contrast in rats using functional magnetic resonance imaging. Neuropharmacology 2004; 46: 379–387
   PubMed Web of Science ®Google Scholar
• Gessa GL, Melis M, Muntoni AL, Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 1998; 341: 39–44
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 2003; 71: 37–48
   PubMed Web of Science ®Google Scholar
• Hall W. Cannabis use and psychosis. Drug Alcohol Rev 1998; 17: 433–444
   PubMed Web of Science ®Google Scholar
• Hall W. Reducing the harms caused by cannabis use: the policy debate in Australia. Drug Alcohol Depend 2001; 62: 163–174
   PubMed Web of Science ®Google Scholar
• Voruganti LNP, Slomka P, Zabel AM, Awad AG. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res Neuroimaging 2001; 107: 173–177
   PubMed Web of Science ®Google Scholar
• Scarr E, Copolov DL, Dean B. A proposed pathological model in the hippocampus of subjects with schizophrenia. Clin Exp Pharmacol Physiol 2001; 28: 70–73
   PubMed Web of Science ®Google Scholar
• Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Soc Biol Psychiatry 2000; 48: 381–388
   PubMed Web of Science ®Google Scholar
• Friedman JI, Adler DN, Davis KL. The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease. Biol Psychiatry 1999; 46: 1243–1252
   PubMed Web of Science ®Google Scholar
• Akinshola BE, Taylor RE, Ogunseitan AB, Onaivi ES. Anandamide inhibition of recombinant AMPA receptor subunits in Xenopus oocytes is increased by forskolin and 8-brumo-cylic AMP. Naunyn Schmiedebergs Arch Pharmacol 1999; 360: 242–248
   PubMed Web of Science ®Google Scholar
• Darmani NA. Cannabinoids of diverse structure inhibit two DOI-induced 5-HT2A receptor-mediated behaviors in mice. Pharmacol Biochem Behav 2001; 68: 311–317
   PubMed Web of Science ®Google Scholar
• Costa E, Cheney DL, Murray TF. Levonantradol-induced inhibition of acetylcholine turnover in rat hippocampus and striatum. J Clin Pharmacol 1981; 21(Suppl 8–9)256S–261
   PubMed Web of Science ®Google Scholar
• Giuffrida A, Leweke FM, Gerth CW, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004; 29: 2108–2114
   PubMed Web of Science ®Google Scholar
• Parrott AC, Gouzoulis-Meyfrank E, Rodgers J, Solowij N. Ecstasy/MDMA and cannabis: the complexities of their interactive neuropsychobiological effects. J Psychopharmacol 2004; 18: 572–575
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995; 56: 485–486
   PubMed Web of Science ®Google Scholar